PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Both PNPLA3 rs738409 c.444 C > G p.I148M and TM6SF2 rs58542926 C > T E167K polymorphisms are quite common in patients in NAFLD, and these polymorphisms may attenuate CVD risk.